INTRODUCTION Novartis recently launched Novartis Access, an initiative to provide a basket of reduced price medicines for non-communicable diseases (NCDs) to be sold through the public and private non-profit sectors in programme countries. This study will evaluate the impact of Novartis Access on the availability and price of NCD medicines at health facilities and households in Kenya, the first...

Genoptix, a Novartis molecular diagnostics company in Carlsbad, CA, introduced the nextgeneration sequencing-based test with the help of the Cambridge researchers for diagnosing non-small cell lung cancer. Marking more progress toward precision medicine in cancer, the test uses information from an individual’s sequenced tumor genes to pinpoint mutations that tip off experts that a patient might...

* To whom correspondence should be addressed. E-mail: [email protected] Editor: Elan D. Louis, Yale University, USA Received: October 16, 2017 Accepted: December 14, 2017 Published: January 8, 2018 Copyright: ’ 2018 Nuermaimaiti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the user ...

Mapi Workshops, Issue Panel, Podium Presentations ISPOR Amsterdam 2014 Tuesday, 11 November / 4:45 PM 5:45 PM W15: MIXED METHODS RESEARCH WITHIN CLINICAL TRIALS: OPERATIONAL CONSIDERATIONS Alexia Marrel, BA, Associate Director, Health Economics and Outcomes Research, Mapi, Lyon, France Frederico Calado, PharmD, Associate Director, Global Patient Assess, Novartis, East Hanover, NJ, USA Jean-Bern...

SCOTT BULL, PHARM.D., is a Pharmacy Research Analyst, Kaiser Permanente Division of Research, Oakland, CA At the time of the study, he was Pharmacoeconomics/Outcomcs Research Fellow, Novartis Pharmaceuticals/Kaiser Permanente. OMAR SHOHEIBER, PHARMD., is Vice PresidcntPmduct Development, Tricore Technologies, North Brunswick, NJ At the time of the study, he was Associate Director, Outcomes Rese...